In this webinar, Dr Laura Savage, Dr Amy Foulkes and Dr John Reed discuss the shape of the patient consultation process in moderate-severe plaque psoriasis and chronic spontaneous urticaria in the COVID-19 era, and what the future may hold for consultations beyond the pandemic. This is followed by a detailed evaluation of the additional support available to healthcare professionals and patients, and we put the You First programme under the microscope (a nurse-led service for dermatology patients) to understand what it can really offer in this time of crisis and also in the future.
You First is a patient support programme developed and funded by Novartis Pharmaceuticals UK Limited. You First is for NHS patients who are receiving Cosentyx (secukinumab) or for whom the prescribing decision has been made. A service level agreement is required for each NHS organisation participating.
Select the menu within the video to enable you to skip between sections.
Cosentyx (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1 Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.
Xolair (omalizumab) is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.2 Xolair treatment should be initiated by physicians experienced in the diagnosis and treatment of CSU.
- Cosentyx® Summary of Product Characteristics.
- Xolair® (omalizumab) 150 mg Summary of Product Characteristics.